Supplementary Material for: Twelve-Month and Lifetime Prevalence of Mental Disorders in Cancer Patients

Background: Psychological problems are common in cancer patients. For the purpose of planning psycho-oncological interventions and services tailored to the specific needs of different cancer patient populations, it is necessary to know to what extent psychological problems meet the criteria of mental disorders. The purpose of this study was to estimate the 12-month and lifetime prevalence rates of mental disorders in cancer patients. Methods: A representative sample of patients with different tumour entities and tumour stages (n = 2,141) in outpatient, inpatient and rehabilitation settings underwent the standardized computer-assisted Composite International Diagnostic Interview for mental disorders adapted for cancer patients (CIDI-O). Results: The overall 12-month prevalence for any mental disorder was 39.4% (95% CI: 37.3-41.5), that for anxiety disorders was 15.8% (95% CI: 14.4-17.4), 12.5% (95% CI: 11.3-14.0) for mood disorders, 9.5% (95% CI: 8.3-10.9) for somatoform disorders, 7.3% (95% CI: 6.2-8.5) for nicotine dependence, 3.7% (95% CI: 3.0-4.6) for disorders due to general medical condition, and 1.1% (95% CI: 0.7-1.6) for alcohol abuse or dependence. Lifetime prevalence for any mental disorder was 56.3% (95% CI 54.1-58.6), that for anxiety disorders was 24.1% (95% CI: 22.3-25.9), 20.5% (95% CI: 18.9-22.3) for mood disorders, 19.9% (95% CI: 18.3-21.7) for somatoform disorders, 18.2% (95% CI: 16.6-20.0) for nicotine dependence, 6.4% (95% CI: 5.4-7.6) for alcohol abuse or dependence, 4.6% (95% CI: 3.8-5.6) for disorders due to general medical condition, and 0.2% (95% CI: 0.1-0.6) for eating disorders. Conclusions: Mental disorders are highly prevalent in cancer patients, indicating the need for provision of continuous psycho-oncological support from inpatient to outpatient care, leading to an appropriate allocation of direct personnel and other resources.

研究背景：肿瘤患者群体中心理问题十分常见。为规划适配不同肿瘤患者人群特定需求的精神肿瘤学（psycho-oncological）干预措施与服务，明确心理问题符合精神障碍诊断标准的比例至关重要。本研究旨在评估肿瘤患者中精神障碍的12个月患病率与终生患病率。
研究方法：本研究纳入门诊、住院及康复机构中不同肿瘤实体（tumour entities）与肿瘤分期的代表性样本共2141例（n=2141），采用针对肿瘤患者适配的标准化计算机辅助精神障碍国际诊断访谈（Composite International Diagnostic Interview for mental disorders adapted for cancer patients，缩写CIDI-O）开展评估。
研究结果：任意类型精神障碍的总体12个月患病率为39.4%（95% CI：37.3~41.5）；其中焦虑障碍（anxiety disorders）为15.8%（95% CI：14.4~17.4），心境障碍（mood disorders）为12.5%（95% CI：11.3~14.0），躯体形式障碍（somatoform disorders）为9.5%（95% CI：8.3~10.9），尼古丁依赖（nicotine dependence）为7.3%（95% CI：6.2~8.5），躯体疾病所致精神障碍（disorders due to general medical condition）为3.7%（95% CI：3.0~4.6），酒精滥用或依赖（alcohol abuse or dependence）为1.1%（95% CI：0.7~1.6）。精神障碍的终生总体患病率为56.3%（95% CI：54.1~58.6）；其中焦虑障碍为24.1%（95% CI：22.3~25.9），心境障碍为20.5%（95% CI：18.9~22.3），躯体形式障碍为19.9%（95% CI：18.3~21.7），尼古丁依赖为18.2%（95% CI：16.6~20.0），酒精滥用或依赖为6.4%（95% CI：5.4~7.6），躯体疾病所致精神障碍为4.6%（95% CI：3.8~5.6），进食障碍（eating disorders）为0.2%（95% CI：0.1~0.6）。
研究结论：肿瘤患者群体中精神障碍患病率极高，提示需在从住院到门诊的全周期医疗服务中提供持续的精神肿瘤学支持，以实现人力与其他相关资源的合理配置。